| Year |
Citation |
Score |
| 2022 |
Goldman S, Margol A, Hwang EI, Tanaka K, Suchorska B, Crawford JR, Kesari S. Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data. Frontiers in Oncology. 12: 958637. PMID 36072789 DOI: 10.3389/fonc.2022.958637 |
0.303 |
|
| 2021 |
Park JH, de Lomana ALG, Marzese DM, Juarez T, Feroze A, Hothi P, Cobbs C, Patel AP, Kesari S, Huang S, Baliga NS. A Systems Approach to Brain Tumor Treatment. Cancers. 13. PMID 34202449 DOI: 10.3390/cancers13133152 |
0.302 |
|
| 2020 |
Rodvold JJ, Xian S, Nussbacher J, Tsui B, Cameron Waller T, Searles SC, Lew A, Jiang P, Babic I, Nomura N, Lin JH, Kesari S, Carter H, Zanetti M. IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells. Scientific Reports. 10: 8348. PMID 32433555 DOI: 10.1038/S41598-020-65320-6 |
0.315 |
|
| 2020 |
Kim MM, Parmar HA, Schipper M, Devasia T, Aryal MP, Kesari S, O'Day S, Morikawa A, Spratt DE, Junck L, Mammoser A, Hayman JA, Lawrence TS, Tsien CI, Aiken R, et al. BRAINSTORM: A Multi-Institutional Phase I/II Study of RRx-001 in Combination with Whole Brain Radiation Therapy for Patients with Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. PMID 32169409 DOI: 10.1016/J.Ijrobp.2020.02.639 |
0.309 |
|
| 2020 |
Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, et al. ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31969331 DOI: 10.1158/1078-0432.Ccr-19-3258 |
0.326 |
|
| 2020 |
Singh VM, Fisher DM, Berz D, Schultz R, Mayer JA, Boorgula S, Nguyen M, Troung J, Dobrawa L, Gill J, Carrillo JA, Kesari S. The next generation of cerebrospinal fluid (CSF)-based molecular diagnostics: Improving sensitivity and actionability in breast and lung cancer patients with CNS involvement. Journal of Clinical Oncology. 38: e14502-e14502. DOI: 10.1200/Jco.2020.38.15_Suppl.E14502 |
0.363 |
|
| 2020 |
Sampson JH, Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner AJ, Chandhasin C, Chowdhary SA, Coello M, Das S, Han SJ, Kesari S, Merchant F, Merchant N, et al. MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. Journal of Clinical Oncology. 38: 2513-2513. DOI: 10.1200/Jco.2020.38.15_Suppl.2513 |
0.365 |
|
| 2020 |
Bota DA, Duma CM, Kesari S, Piccioni DE, LaRocca RV, O'Donnell RT, Aiken RD, Carrillo JA, Hsieh C, Langford CJ, Carta K, Wang AM, Langford JA, Taylor TH, Nistor GI, et al. Abstract CT182: Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct182 |
0.403 |
|
| 2019 |
Loya J, Zhang C, Cox E, Achrol AS, Kesari S. Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. Cns Oncology. 8: CNS38. PMID 31747788 DOI: 10.2217/Cns-2019-0001 |
0.339 |
|
| 2019 |
Loya J, Zhang C, Cox E, Achrol AS, Kesari S. Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy. Cns Oncology. 8: CNS40. PMID 31747784 DOI: 10.2217/Cns-2019-0002 |
0.35 |
|
| 2019 |
Minev BR, Lander E, Feller JF, Berman M, Greenwood BM, Minev I, Santidrian AF, Nguyen D, Draganov D, Killinc MO, Vyalkova A, Kesari S, McClay E, Carabulea G, Marincola FM, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. Journal of Translational Medicine. 17: 271. PMID 31426803 DOI: 10.1186/S12967-019-2011-3 |
0.342 |
|
| 2019 |
Sivakumar W, Barkhoudarian G, Lobo BM, Zhang X, Zhao F, Eisenberg A, Kesari S, Krauss H, Cohan P, Griffiths C, Wollman R, Chaiken L, Kelly DF. Strategy and technique of endonasal endoscopic bony decompression and selective tumor removal in symptomatic skull base meningiomas of the cavernous sinus and Meckel's cave. World Neurosurgery. PMID 31226453 DOI: 10.1016/J.Wneu.2019.06.073 |
0.328 |
|
| 2019 |
Piccioni DE, Achrol AS, Kiedrowski LA, Banks KC, Boucher N, Barkhoudarian G, Kelly DF, Juarez T, Lanman RB, Raymond VM, Nguyen M, Truong JD, Heng A, Gill J, Saria M, ... ... Kesari S, et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. Cns Oncology. PMID 30855176 DOI: 10.2217/Cns-2018-0015 |
0.378 |
|
| 2019 |
Cobbs C, McClay E, Duic JP, Nabors LB, Murray DM, Kesari S. An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. Cns Oncology. 8. PMID 30547676 DOI: 10.2217/Cns-2018-0013 |
0.304 |
|
| 2019 |
Carrillo JA, Kesari S. Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat? Translational Cancer Research. 8: 4-6. DOI: 10.21037/25233 |
0.39 |
|
| 2019 |
Mason WP, Kesari S, Stupp R, Aregawi DG, Piccioni DE, Roth P, Desjardins A, Reich SD, Casadebaig M, Elias I, Winograd B, Levin N, Bota DA. Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 37: 2021-2021. DOI: 10.1200/Jco.2019.37.15_Suppl.2021 |
0.351 |
|
| 2019 |
Kesari S, Juarez T, Carrillo J, Truong J, Nguyen M, Heng A, Gill J, Nguyen H, Nomura N, Grigorian B, Hou S, Schmid A, Desai N. RBTT-01. A PHASE 2 TRIAL WITH ABI-009 (NAB-SIROLIMUS) AS SINGLE-AGENT AND COMBINATIONS IN RECURRENT HIGH-GRADE GLIOMA (rHGG) AND IN NEWLY DIAGNOSED GLIOBLASTOMA (ndGBM) Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.913 |
0.313 |
|
| 2019 |
Chang A, Gardner S, Jaboin J, Leary S, Mola RLD, McClay E, Murray DM, Nazemi K, Panandiker AP, Salacz M, Stapleton S, Kesari S, Prados M. Pdct-07. Early Results Of The Emulate Therapeutics Hælo™ System In Pediatric Brain Tumors Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.770 |
0.352 |
|
| 2019 |
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. Actr-69. Feasibility Study Of The Emulate Therapeutics™ Voyager System In Patients With Newly Diagnosed Glioblastoma Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.110 |
0.315 |
|
| 2019 |
Barkhoudarian G, Badruddoja M, Blondin N, Chen R, Chowdhary S, Cobbs C, Dowling A, Duic P, Flores JP, Fonkem E, McClay E, Nabors L, Salacz M, Vaillant B, Kesari S. Actr-68. Feasibility Study Of The Emulate Therapeutics™ Voyager System In Patients With Recurrent Glioblastoma (Gbm) Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.109 |
0.339 |
|
| 2018 |
George E, Kijewski MF, Dubey S, Belanger AP, Reardon DA, Wen PY, Kesari S, Horky L, Park MA, Huang RY. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. Ajr. American Journal of Roentgenology. 1-6. PMID 30332289 DOI: 10.2214/Ajr.18.19988 |
0.325 |
|
| 2018 |
Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, et al. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. International Journal of Cancer. PMID 29923182 DOI: 10.1002/Ijc.31624 |
0.385 |
|
| 2018 |
Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A. Rethinking medulloblastoma from a targeted therapeutics perspective. Journal of Neuro-Oncology. PMID 29869738 DOI: 10.1007/S11060-018-2917-2 |
0.33 |
|
| 2018 |
Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. Journal of Neuro-Oncology. PMID 29846894 DOI: 10.1007/S11060-018-2891-8 |
0.303 |
|
| 2018 |
Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Kesari S, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/S12967-018-1507-6 |
0.32 |
|
| 2018 |
Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, et al. Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC. Neuro-Oncology. PMID 29762717 DOI: 10.1093/Neuonc/Noy075 |
0.359 |
|
| 2018 |
Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 9: 7822-7831. PMID 29487694 DOI: 10.18632/Oncotarget.23288 |
0.304 |
|
| 2018 |
Bota DA, Kesari S, Piccioni DE, Aregawi DG, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason WP. A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E14083 |
0.363 |
|
| 2018 |
Walbert T, Lavy-Shahaf G, Toms SA, Kesari S. Abstract CT100: Tumor treating fields (TTFields) on health-related quality of life (HRQoL) in ndGBM: An exploratory analysis of the EF-14 phase III trial Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct100 |
0.342 |
|
| 2018 |
Babic I, Nomura N, Glassy E, Nurmemmedov E, Yenugonda V, Glassy M, Kesari S. Abstract 3828: Pritumumab mAb binds cell surface expressed vimentin on pancreatic cancer cells and inhibits tumor growth Cancer Research. 78: 3828-3828. DOI: 10.1158/1538-7445.Am2018-3828 |
0.356 |
|
| 2018 |
Cloughesy TF, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen CC, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Mikkelsen T, Nghiemphu L, Piccioni D, et al. Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A085 |
0.409 |
|
| 2018 |
Dardis C, Phuphanich S, Sanai N, Xiu J, Mittal S, Michelhaugh S, Subramaniam D, Pandey M, Kesari S, Heimberger A, Gatalica Z, Korn WM, Sumrall A. Rare-05. Tumor Profiling Reveals Epithelial-To-Mesenchymal Transition (Emt) And Enhanced Immune Suppression In Gliosarcomas Relative To Glioblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.983 |
0.311 |
|
| 2018 |
Kim M, Parmar H, Aryal M, Schipper M, Devasia T, Kesari S, Morikawa A, Spratt D, Junck L, Hayman J, Lawrence T, Tsien C, Aiken R, Goyal S, Knox S, et al. CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES Neuro-Oncology. 20: vi63-vi63. DOI: 10.1093/Neuonc/Noy148.255 |
0.316 |
|
| 2018 |
Bota DA, Kesari S, Piccioni D, Aregawi D, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason W. ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.073 |
0.323 |
|
| 2018 |
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. Actr-26. A Feasibility Study Of The Nativis Voyager® System In Patients With Newly Diagnosed Glioblastoma (Gbm) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.059 |
0.331 |
|
| 2018 |
Bexon MF, Achrol A, Bankiewicz K, Brenner A, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy273.368 |
0.336 |
|
| 2018 |
Mikkelsen T, Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder J, Chen C, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Nghiemphu P, Piccioni D, Accomando W, et al. 25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S11-S11. DOI: 10.1017/Cjn.2018.290 |
0.405 |
|
| 2017 |
Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. PMID 29211306 DOI: 10.1002/Cncr.31175 |
0.311 |
|
| 2017 |
Wang G, Benasutti H, Jones JF, Shi G, Benchimol M, Pingle S, Kesari S, Yeh Y, Hsieh LE, Liu YT, Elias A, Simberg D. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids and Surfaces. B, Biointerfaces. 161: 200-209. PMID 29080504 DOI: 10.1016/J.Colsurfb.2017.10.060 |
0.333 |
|
| 2017 |
Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, Kesari S, Babic I. A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. Journal of Translational Medicine. 15: 210. PMID 29047383 DOI: 10.1186/S12967-017-1312-7 |
0.306 |
|
| 2017 |
Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S. Pritumumab, the first therapeutic antibody for glioma patients. Human Antibodies. PMID 29036806 DOI: 10.3233/Hab-170326 |
0.352 |
|
| 2017 |
Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature Neuroscience. PMID 28604685 DOI: 10.1038/Nn.4584 |
0.3 |
|
| 2017 |
Tao Z, Li S, Ichim TE, Yang J, Riordan N, Yenugonda V, Babic I, Kesari S. Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy. 9: 589-606. PMID 28595516 DOI: 10.2217/Imt-2016-0086 |
0.375 |
|
| 2017 |
Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, et al. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. International Journal of Molecular Sciences. 18. PMID 28481241 DOI: 10.3390/Ijms18050995 |
0.385 |
|
| 2017 |
Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, Kesari S. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine. Oncotarget. PMID 28404894 DOI: 10.18632/Oncotarget.15563 |
0.354 |
|
| 2017 |
Kesari S, Ram Z. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. Cns Oncology. PMID 28399638 DOI: 10.2217/Cns-2016-0049 |
0.364 |
|
| 2017 |
Krishnan AP, Karunamuni R, Leyden KM, Seibert TM, Delfanti RL, Kuperman JM, Bartsch H, Elbe P, Srikant A, Dale AM, Kesari S, Piccioni DE, Hattangadi-Gluth JA, Farid N, McDonald CR, et al. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. Ajnr. American Journal of Neuroradiology. PMID 28279985 DOI: 10.3174/Ajnr.A5099 |
0.333 |
|
| 2017 |
Saria MG, Nyamathi A, Phillips LR, Stanton AL, Evangelista L, Kesari S, Maliski S. The Hidden Morbidity of Cancer: Burden in Caregivers of Patients with Brain Metastases. The Nursing Clinics of North America. 52: 159-178. PMID 28189161 DOI: 10.1016/J.Cnur.2016.10.002 |
0.309 |
|
| 2017 |
Babic I, Mukthavaram R, Jiang P, Nomura N, Glassy E, Glassy MC, Kesari S. Analysis of hybridoma and CHO-derived pritumumab for therapeutic applications. Journal of Clinical Oncology. 35: 71-71. DOI: 10.1200/Jco.2017.35.7_Suppl.71 |
0.325 |
|
| 2017 |
Lanman TA, Kesari S, Patel SP, Bazhenova L, Parker BA, Daniels GA, Fanta PT, Plaxe SC, Schwaederle MC, Kurzrock R, Piccioni DE. Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 35: e13546-e13546. DOI: 10.1200/Jco.2017.35.15_Suppl.E13546 |
0.35 |
|
| 2017 |
Cloughesy TF, Ostertag D, Landolfi JC, Walbert T, Vogelbaum MA, Elder JB, Bloomfield S, Carter B, Chen C, Kalkanis SN, Kesari S, Lai A, Lee I, Liau LM, Mikkelsen T, et al. Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. Journal of Clinical Oncology. 35: e13504-e13504. DOI: 10.1200/Jco.2017.35.15_Suppl.E13504 |
0.395 |
|
| 2017 |
Ibrahim N, Tang S, Brenner A, Kesari S, Piccioni D, Anders C, Carillo J, Chalasani P, Kabos P, Puhalla S, Garcia A, Tkaczuk K, Lakhani N, Kumthekar P. Abstract P1-12-01: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-12-01 |
0.365 |
|
| 2017 |
Babic I, Mukthavaram R, Jiang P, Glassy E, Nomura N, Pingle S, Glassy MC, Kesari S. Abstract 5611: Use of ecto-domain vimentin to target brain cancers Cancer Research. 77: 5611-5611. DOI: 10.1158/1538-7445.Am2017-5611 |
0.374 |
|
| 2017 |
Nguyen M, Truong J, Saria M, Kesari S. Qlif-16. Clinical And Social Challenges & Opportunities In Treating Glioblastoma With Tumor Treatment Fields, A Case Series Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.826 |
0.308 |
|
| 2017 |
Alton G, Beaton G, Knowles S, Guerrero A, Kesari S, Stein G. Exth-18. Ct-179 Selectively Targets Olig2-Positive Glioma Stem Cells And Demonstrates Potent Anti-Tumor Activity In Glioblastoma Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.313 |
0.318 |
|
| 2017 |
Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, et al. CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS Neuro-Oncology. 19: vi40-vi41. DOI: 10.1093/Neuonc/Nox168.158 |
0.311 |
|
| 2017 |
Juarez T, Boucher N, Heng A, Gill J, Nguyen M, Truong J, Saria M, Achrol A, Barkhoudarian G, Kelly D, Kesari S. Actr-62. A Phase Ii Study Of Tumor Treating Fields (Ttfields) With Temozolomide In Patients With Low-Grade Gliomas Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.051 |
0.351 |
|
| 2017 |
Kesari S, Tran D, Read W, Ahluwalia M, Villano J, Toms S, Zhu J, Ram Z. Actr-55. Tumor Treating Fields With Second Line Treatment Compared To Second Line Treatment Alone In Patients At First Recurrence Of Glioblastoma – A Post Hoc Analysis Of The Ef-14 Phase 3 Clinical Trial Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.046 |
0.338 |
|
| 2017 |
Bota D, Mason W, Kesari S, Piccioni D, Aregawi D, Desjardins A, Winograd B, Reich SD, Levin N, Trikha M. ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.036 |
0.319 |
|
| 2017 |
Barkhoudarian G, Cobbs C, McClay E, Vaillant B, Duic JP, Nabors B, Ellingson B, Sheffield D, Kesari S. Actr-41. Interim Results Of First-In-Human Study Using Nativis Voyager™ System In Patients With Recurrent Glioblastoma (Gbm) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.032 |
0.314 |
|
| 2017 |
Juarez T, Boucher N, Heng A, Gill J, Nguyen M, Truong J, Saria M, Achrol A, Barkhoudarian G, Kelly D, Kesari S. Actr-33. A Phase I Dose Escalation And Central Nervous System (Cns) Pharmacokinetic Study Of Pulsatile Afatinib In Patients With Brain Cancer Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.026 |
0.319 |
|
| 2017 |
Sivakumar W, Lobo B, Zhang X, Zhao F, Amy E, Kesari S, Wollman R, Chaiken L, Cohan P, Griffiths C, Barkhoudarian G, Kelly D. Endonasal Endoscopic Bony Decompression, Limited Tumor Removal and Stereotactic Radiation Therapy in Invasive Parasellar Meningiomas to Improve Cranial Neuropathy and Endocrinopathy Skull Base Surgery. 78. DOI: 10.1055/S-0037-1600628 |
0.331 |
|
| 2017 |
Makale MT, Kesari S, Wrasidlo W. The autonomic nervous system and cancer Biocybernetics and Biomedical Engineering. 37: 443-452. DOI: 10.1016/J.Bbe.2017.05.001 |
0.383 |
|
| 2016 |
Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW. RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. Oncotarget. PMID 27829215 DOI: 10.18632/Oncotarget.13084 |
0.428 |
|
| 2016 |
Saria MG, Kesari S. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy. Clinical Journal of Oncology Nursing. 20: 9. PMID 27668388 DOI: 10.1188/16.Cjon.S1.9-13 |
0.392 |
|
| 2016 |
Jiang P, Zhang P, Mukthavaram R, Nomura N, Pingle SC, Teng D, Chien S, Guo F, Kesari S. Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells. Oncotarget. PMID 27462771 DOI: 10.18632/Oncotarget.10773 |
0.33 |
|
| 2016 |
Stupp R, Toms SA, Kesari S. Treatment for Patients With Newly Diagnosed Glioblastoma--Reply. Jama. 315: 2348-2349. PMID 27272591 DOI: 10.1001/Jama.2016.1847 |
0.304 |
|
| 2016 |
Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75. PMID 27252174 DOI: 10.1126/Scitranslmed.Aad9784 |
0.361 |
|
| 2016 |
Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185373 DOI: 10.1158/1078-0432.Ccr-16-0318 |
0.346 |
|
| 2016 |
Wagner SC, Riordan NH, Ichim TE, Szymanski J, Ma H, Perez JA, Lopez J, Plata-Munoz JJ, Silva F, Patel AN, Kesari S. Safety of targeting tumor endothelial cell antigens. Journal of Translational Medicine. 14: 90. PMID 27071457 DOI: 10.1186/S12967-016-0842-8 |
0.341 |
|
| 2016 |
Xiu J, Piccioni D, Juarez T, Pingle SC, Hu J, Rudnick J, Fink K, Spetzler DB, Maney T, Ghazalpour A, Bender R, Gatalica Z, Reddy S, Sanai N, Idbaih A, ... ... Kesari S, et al. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Oncotarget. PMID 26933808 DOI: 10.18632/Oncotarget.7722 |
0.335 |
|
| 2016 |
Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology. PMID 26902851 DOI: 10.1093/Neuonc/Now009 |
0.332 |
|
| 2016 |
Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology. PMID 26902850 DOI: 10.1093/Neuonc/Now007 |
0.318 |
|
| 2016 |
Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. PMID 26873727 DOI: 10.1158/1535-7163.MCT-15-0795 |
0.349 |
|
| 2016 |
Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. PMID 26848768 DOI: 10.18632/oncotarget.7110 |
0.307 |
|
| 2016 |
Xiu J, Reddy SK, Kesari S, McLaughlin SE, Hohl RJ, Barger G, Heimberger AB. Comparison of molecular alteration in glioblastoma tumors from old and young patients. Journal of Clinical Oncology. 34: 2056-2056. DOI: 10.1200/Jco.2016.34.15_Suppl.2056 |
0.342 |
|
| 2016 |
Cloughesy TF, Aghi MK, Chen C, Elder JB, Kesari S, Kalkanis SN, Kaptain G, Landolfi JC, Mikkelsen T, Portnow J, Robbins JM, Ostertag D, Das A, Chu A, Vogelbaum MA. Encouraging survival with Toca 511 and Toca FC compared to external lomustine control. Journal of Clinical Oncology. 34: 2030-2030. DOI: 10.1200/Jco.2016.34.15_Suppl.2030 |
0.351 |
|
| 2016 |
Faiq N, Patel SP, Bazhenova L, Parker BA, Plaxe SC, Kurzrock R, Kesari S, Piccioni DE. Characterization of cell-free circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 34: 2023-2023. DOI: 10.1200/Jco.2016.34.15_Suppl.2023 |
0.396 |
|
| 2016 |
Kumthekar P, Tang S, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla S, Garcia AA, Tkaczuk KH, Ahluwalia MS, Lakhani NJ, Ibrahim NK. ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer. Journal of Clinical Oncology. 34: 2004-2004. DOI: 10.1200/Jco.2016.34.15_Suppl.2004 |
0.311 |
|
| 2016 |
Tang S, Bates S, Kesari S, Brenner A, Anders C, Garcia A, Ibrahim N, Tkaczuk K, Kumthekar P. Abstract P6-17-04: A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant taxane derivative, in breast cancer patients with recurrent CNS metastases Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-17-04 |
0.398 |
|
| 2016 |
Wang G, Pingle S, Kesari S, Liu Y, Simberg D. Abstract 357: Rapid harvesting of highly concentrated circulating tumor cells from bulk human blood with buoyant immuno-microbubbles Cancer Research. 76: 357-357. DOI: 10.1158/1538-7445.Am2016-357 |
0.377 |
|
| 2016 |
Alton G, Beaton G, Knowles S, Stein G, Mukthavaam R, Kesari S. Abstract 3030: CT179: A novel small molecule Olig2 inhibitor for the treatment of glioblastoma Cancer Research. 76: 3030-3030. DOI: 10.1158/1538-7445.Am2016-3030 |
0.36 |
|
| 2016 |
Babic I, Mukthavaram R, Nomura N, Pingle S, Glassy MC, Kesari S. Abstract 2357: Therapeutic potential of the natural human IgG1k antibody pritumumab Cancer Research. 76: 2357-2357. DOI: 10.1158/1538-7445.Am2016-2357 |
0.363 |
|
| 2016 |
Sanai N, Xiu J, Kim L, Kesari S, Zhou S, Groot Jd, Heimberger A. Rare-38. Novel Targets In Ependymal Tumors Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.701 |
0.338 |
|
| 2016 |
Crawford J, Dhall G, Margol A, Saria M, Kesari S. Nimg-66. Clinical Experiences Of Tumor Treating Fields (Ttfields) In Pediatric Patients With Gbm Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.577 |
0.346 |
|
| 2016 |
Saria M, Nguyen M, Truong J, Heng A, Boucher N, Eisenberg A, Kesari S. Nimg-63. Optimal Patient And Family Education Is Key To Improving The Efficacy Of Tumor Treating Fields Plus Chemotherapy In Treatment Of Gbm Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.574 |
0.329 |
|
| 2016 |
Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C, Carrillo J, Chalasani P, Kabos P, Ahluwalia MS, Ibrahim N. Bmet-28. The Novel Brain Penetrating Peptide-Drug Conjugate Ang1005 Shows Activity In Lc Subset Of Patients With Recurrent Cns Metastasis From Breast Cancer Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.128 |
0.311 |
|
| 2016 |
Kumthekar P, Tang S, Brenner AJ, Kesari S, Anders CK, Carrillo JA, Chalasani P, Kabos P, Ahluwalia MS, Ibrahim NK. OS7.2 A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now188.052 |
0.322 |
|
| 2016 |
Tang S, Kumthekar P, Brenner AJ, Kesari S, Piccioni D, Anders CK, Carillo JA, Chalasani P, Kabos P, Puhalla SL, Garcia A, Tkaczuk K, Ahluwalia MS, Lakhani N, Ibrahim N. ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw367.02 |
0.301 |
|
| 2015 |
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. Jama. 314: 2535-43. PMID 26670971 DOI: 10.1001/Jama.2015.16669 |
0.39 |
|
| 2015 |
Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, et al. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. American Journal of Clinical Oncology. PMID 26658237 DOI: 10.1097/Coc.0000000000000247 |
0.348 |
|
| 2015 |
Scott BJ, Oberheim-Bush NA, Kesari S. Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget. PMID 26543235 DOI: 10.18632/Oncotarget.5911 |
0.328 |
|
| 2015 |
Wagner SC, Ichim TE, Ma H, Szymanski J, Perez JA, Lopez J, Bogin V, Patel AN, Marincola FM, Kesari S. Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique? Journal of Translational Medicine. 13: 340. PMID 26510973 DOI: 10.1186/S12967-015-0688-5 |
0.347 |
|
| 2015 |
Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. PMID 26418953 DOI: 10.18632/Oncotarget.5289 |
0.397 |
|
| 2015 |
Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, Kesari S. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. Journal of Translational Medicine. 13: 269. PMID 26283544 DOI: 10.1186/S12967-015-0627-5 |
0.332 |
|
| 2015 |
Saria MG, Piccioni D, Carter J, Orosco H, Turpin T, Kesari S. Current Perspectives in the Management of Brain Metastases. Clinical Journal of Oncology Nursing. 19: 475-9. PMID 26207714 DOI: 10.1188/15.Cjon.475-478 |
0.34 |
|
| 2015 |
Alentorn A, Duran-Peña A, Pingle SC, Piccioni DE, Idbaih A, Kesari S. Molecular profiling of gliomas: potential therapeutic implications. Expert Review of Anticancer Therapy. 15: 955-62. PMID 26118895 DOI: 10.1586/14737140.2015.1062368 |
0.378 |
|
| 2015 |
Jadin L, Pastorino S, Symons R, Nomura N, Jiang P, Juarez T, Makale M, Kesari S. Hyaluronan expression in primary and secondary brain tumors. Annals of Translational Medicine. 3: 80. PMID 25992379 DOI: 10.3978/J.Issn.2305-5839.2015.04.07 |
0.386 |
|
| 2015 |
Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle (Georgetown, Tex.). 14: 1730-7. PMID 25928476 DOI: 10.1080/15384101.2015.1033596 |
0.346 |
|
| 2015 |
Ichim TE, Li S, Ma H, Yurova YV, Szymanski JS, Patel AN, Kesari S, Min WP, Wagner SC. Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™. Journal of Translational Medicine. 13: 90. PMID 25889119 DOI: 10.1186/S12967-015-0441-0 |
0.374 |
|
| 2015 |
Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 6: 4527-36. PMID 25784657 DOI: 10.18632/Oncotarget.2886 |
0.333 |
|
| 2015 |
Le AP, Huang Y, Pingle SC, Kesari S, Wang H, Yong RL, Zou H, Friedel RH. Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget. 6: 7293-304. PMID 25762646 DOI: 10.18632/Oncotarget.3421 |
0.311 |
|
| 2015 |
Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle (Georgetown, Tex.). 14: 1252-9. PMID 25695927 DOI: 10.1080/15384101.2015.1014149 |
0.345 |
|
| 2015 |
Lyday B, Chen T, Kesari S, Minev B. Overcoming tumor immune evasion with an unique arbovirus. Journal of Translational Medicine. 13: 3. PMID 25592450 DOI: 10.1186/S12967-014-0349-0 |
0.353 |
|
| 2015 |
Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho YJ, Pingle SC, Crawford JR, Piccioni DE, Kesari S. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget. 6: 1157-70. PMID 25528767 DOI: 10.18632/Oncotarget.2708 |
0.307 |
|
| 2015 |
Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investigational New Drugs. 33: 247-53. PMID 25388940 DOI: 10.1007/S10637-014-0186-2 |
0.326 |
|
| 2015 |
Holcombe RF, Xiu J, Pishvaian MJ, Millis SZ, Gatalica Z, Reddy SK, Sicklick JK, Fanta PT, Kesari S, Morse MA. Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets. Journal of Clinical Oncology. 33: 285-285. DOI: 10.1200/Jco.2015.33.3_Suppl.285 |
0.325 |
|
| 2015 |
Jiang P, Mukthavaram R, Nomura N, Pingle SC, Kesari S. Anti-cancer effects of zoledronic acid on human cancer cells. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13042 |
0.303 |
|
| 2015 |
Pingle SC, Juarez T, Saria MG, Kesari S. CSF pharmacokinetics of high-dose pulsatile tyrosine kinase therapy in brain cancer patients. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13032 |
0.338 |
|
| 2015 |
Faiq N, Chmielecki J, Goldberg M, Stephens P, Kurzrock R, Kesari S, Piccioni DE. Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma. Journal of Clinical Oncology. 33: 2074-2074. DOI: 10.1200/Jco.2015.33.15_Suppl.2074 |
0.302 |
|
| 2015 |
Kesari S, Xiu J, Hu JL, Salacz ME, Piccioni DE, Reddy SK. Tumor profiles of brain metastases from NSCLC, breast cancer, and melanoma. Journal of Clinical Oncology. 33: 2060-2060. DOI: 10.1200/Jco.2015.33.15_Suppl.2060 |
0.373 |
|
| 2015 |
Xiu J, Spetzler D, Bender R, Ghazalpour A, Gatalica Z, Reddy SK, Piccioni DE, Hu JL, Glantz MJ, Kesari S. Tumor profiling on 1245 gliomas and paired tumor study on 19 high grade gliomas. Journal of Clinical Oncology. 33: 2058-2058. DOI: 10.1200/Jco.2015.33.15_Suppl.2058 |
0.38 |
|
| 2015 |
Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, ... ... Kesari S, et al. Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. Journal of Clinical Oncology. 33: 2036-2036. DOI: 10.1200/Jco.2015.33.15_Suppl.2036 |
0.335 |
|
| 2015 |
Stupp R, Taillibert S, Kanner A, Kesari S, Toms SA, Barnett GH, Fink KL, Silvani A, Lieberman FS, Zhu J, Taylor LP, Honnorat J, Hottinger A, Chen T, Tran DD, et al. Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. Journal of Clinical Oncology. 33: 2000-2000. DOI: 10.1200/Jco.2015.33.15_Suppl.2000 |
0.37 |
|
| 2015 |
Piccioni DE, Lanman RB, Nagy RJ, Talasaz A, Pingle SC, Kesari S. Analysis of cell-free circulating tumor DNA in patients with glioblastoma and other primary brain tumors. Journal of Clinical Oncology. 33: 11072-11072. DOI: 10.1200/Jco.2015.33.15_Suppl.11072 |
0.383 |
|
| 2015 |
Chmielecki J, Goldberg ME, Fichtenholtz A, Elvin J, Frampton GM, Ali SM, Ross JS, Morosini D, Miller VA, Piccioni D, Kesari S, Stephens PJ. Abstract 4667: The complex genomic landscape of glial tumors reveals distinct subclasses and potential therapeutic targets associated with clinical responses to targeted inhibitors Cancer Research. 75: 4667-4667. DOI: 10.1158/1538-7445.Am2015-4667 |
0.317 |
|
| 2015 |
Schwaederle MC, Piccioni DE, Kesari S, Husain H, Patel SP, Kurzrock R. Abstract C19: Use of liquid biopsies in clinical oncology: the UCSD Moores Cancer Center experience in 168 patients with diverse malignancies Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C19 |
0.389 |
|
| 2015 |
Aghi M, Vogelbaum MA, Cloughesy T, Kaptain G, Portnow J, Ostertag D, Keller MR, Niethammer A, Chu A, Kesari S. SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 17: v216.2-v216. DOI: 10.1093/Neuonc/Nov235.10 |
0.351 |
|
| 2015 |
Arguello D, Abbott B, Reddy S, Gatalica Z, Kesari S, Sender L. Ptps-01Molecular Profiling Analysis Of Select Pediatric Neuroepithelial Tumors Of The Central Nervous System Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov228.01 |
0.387 |
|
| 2015 |
Kesari S, Landolfi J, Mikkelsen T, Aghi M, Vogelbaum MA, Elder JB, Cobbs C, Singer S, Robbins JM, Ostertag D, Jolly DJ, Chu A, Keller MR, Niethammer A, Cloughesy TF. IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS Neuro-Oncology. 17: v108.1-v108. DOI: 10.1093/Neuonc/Nov218.05 |
0.382 |
|
| 2015 |
Ostertag D, Hogan D, Vogelbaum M, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Chen C, Niethammer A, Chu A, Jolly D, Gruber H, Cloughesy T. GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE Neuro-Oncology. 17: v98.2-v98. DOI: 10.1093/Neuonc/Nov215.30 |
0.392 |
|
| 2015 |
Pingle S, Langley E, Juarez T, Saria M, Meyer G, Kim P, Kesari S. Ddel-17Csf Pharmacokinetics And Pharmacodynamics In Brain Cancer Patients On High-Dose Erlotinib Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov212.17 |
0.371 |
|
| 2015 |
Landolfi J, Cloughesy T, Vogelbaum MA, Kesari S, Piccioni DE, Kalkanis SN, Portnow J, Mikkelsen T, Elder JB, Baskin D, Chu A, Niethammer A, Gruber H, Cobbs C, Foltz G, et al. DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL Neuro-Oncology. 17: v74.4-v75. DOI: 10.1093/Neuonc/Nov212.08 |
0.392 |
|
| 2015 |
Kalkanis SN, Aghi MK, Cloughsy TF, Kaptain G, Portnow J, Vogelbaum MA, Kesari S, Mikkelsen T, Elder JB, Chen CC, Piccioni D, Baskin D, Engh J, Bota D, Chiocca EA, et al. Ddel-06Preliminary Safety Of Toca 511, A Retroviral Replicating Vector, In Patients With Recurrent High Grade Glioma Across Three Separate Phase 1 Studies Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov212.06 |
0.394 |
|
| 2015 |
Faiq N, Lee M, Banks K, Lanman R, Pingle S, Kesari S, Piccioni D. Cbm-13Characterization Of Cell-Free Circulating Tumor Dna In Low Grade And Malignant Gliomas. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov211.13 |
0.359 |
|
| 2015 |
Kesari S, Xiu J, Hu J, Salacz M, Piccioni D, Reddy S. Bmet-36Tumor Profiles Of Brain Metastases From Nsclc, Breast Cancer And Melanoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov208.36 |
0.351 |
|
| 2015 |
Kumthekar P, Bates S, Kesari S, Brenner A, Anders C, Garcia A, Ibrahim N, Tkaczuk K, Tang S. Bmet-23Ang1005, A Novel Brain-Penetrant Peptide-Taxane Conjugate, For The Treatment Of Cns Metastases From Breast Cancer Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov208.23 |
0.385 |
|
| 2015 |
Robins HI, Zhang P, Gilbert M, Chakravarti A, deGroot J, Grimm S, Wang F, Lieberman F, Krauze A, Sharma A, Mohile N, Kee A, Colman H, Cavaliere R, Kesari S, et al. Atct-27Nrg Oncology/Rtog 0929: A Randomized Phase I/Ii Study Of Abt-888In Combination With Temozolomide In Recurrent Temozolomide Resistant Glioblastoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.27 |
0.307 |
|
| 2015 |
Piccioni D, Juarez T, Brown B, Rose L, Allgood V, Kesari S. Atct-18Phase Ii Study Of Mipsagargin (G-202), A Psma-Activated Prodrug Targeting The Tumor Endothelium, In Adult Patients With Recurrent Or Progressive Glioblastoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.18 |
0.416 |
|
| 2015 |
Kesari S, Ram Z. Atnt-19Tumor Treating Fields With Chemotherapy Compared To Chemotherapy Alone In Glioblastoma Patients At First Recurrence: A Post-Hoc Analysis Of The Ef-14 Trial. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov205.19 |
0.37 |
|
| 2015 |
Juarez T, Piccioni D, Nguyen A, Brown B, Rose L, Pu M, Messer K, Kesari S. Atnt-13A Phase I Dose Escalation And Central Nervous System (Cns) Pharmacokinetic Study Of Dexanabinol In Patients With Brain Cancer Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov205.13 |
0.341 |
|
| 2015 |
Mukthavaram R, Jiang P, Nomura N, Pingle S, Butters J, Butters B, Kesari S. Atps-64Preclinical Studies Using Nativis Voyager Rfe System, A Novel Non-Invasive, Low Energy, Non-Thermal, Non-Ionizing Radiofrequency Energy (Rfe) Device In Glioblastoma Mouse Models Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.64 |
0.324 |
|
| 2014 |
Mrugala MM, Engelhard HH, Butowski N, Tran DD, Kew Y, Cavaliere R, Villano J, Bota D, Kesari S, Rudnick J, Sumrall A, Zhu JJ, Wong ET. 415OALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA - NOVOTTF-100A SYSTEM: UPDATED OUTCOMES AND TOXICITY BASED ON THE ANALYSIS OF PATIENT REGISTRY DATA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv137. PMID 28170762 DOI: 10.1093/Annonc/Mdu330.2 |
0.328 |
|
| 2014 |
van Vugt VA, Piccioni DE, Brown BD, Brown T, Saria MG, Juarez T, Kesari S. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. Cns Oncology. 3: 257-65. PMID 25286037 DOI: 10.2217/Cns.14.29 |
0.358 |
|
| 2014 |
White NS, McDonald C, McDonald CR, Farid N, Kuperman J, Karow D, Schenker-Ahmed NM, Bartsch H, Rakow-Penner R, Holland D, Shabaik A, Bjørnerud A, Hope T, Hattangadi-Gluth J, Liss M, ... ... Kesari S, et al. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. Cancer Research. 74: 4638-52. PMID 25183788 DOI: 10.1158/0008-5472.Can-13-3534 |
0.313 |
|
| 2014 |
Farid N, Almeida-Freitas DB, White NS, McDonald CR, Kuperman JM, Almutairi AA, Muller KA, VandenBerg SR, Kesari S, Dale AM. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). Journal of Neuro-Oncology. 120: 539-46. PMID 25135423 DOI: 10.1007/S11060-014-1583-2 |
0.37 |
|
| 2014 |
Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, ... Kesari S, et al. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. Journal of Neuro-Oncology. 119: 361-8. PMID 24942463 DOI: 10.1007/S11060-014-1486-2 |
0.399 |
|
| 2014 |
Pingle SC, Sultana Z, Pastorino S, Jiang P, Mukthavaram R, Chao Y, Bharati IS, Nomura N, Makale M, Abbasi T, Kapoor S, Kumar A, Usmani S, Agrawal A, Vali S, ... Kesari S, et al. In silico modeling predicts drug sensitivity of patient-derived cancer cells. Journal of Translational Medicine. 12: 128. PMID 24884660 DOI: 10.1186/1479-5876-12-128 |
0.305 |
|
| 2014 |
Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, Kesari S. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell International. 14: 26. PMID 24645697 DOI: 10.1186/1475-2867-14-26 |
0.357 |
|
| 2014 |
Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. Journal of Neuro-Oncology. 116: 89-97. PMID 24162827 DOI: 10.1007/S11060-013-1283-3 |
0.41 |
|
| 2014 |
Pastorino S, Langley EJ, Chao Y, Jiang P, Mukthavaram R, Pingle SC, Kim PS, Singh S, Kesari S. Mechanisms of resistance to PDGFR inhibition in glioblastoma. Journal of Clinical Oncology. 32: e13030-e13030. DOI: 10.1200/Jco.2014.32.15_Suppl.E13030 |
0.355 |
|
| 2014 |
Robbins JM, Huang TT, Jolly DJ, Kasahara N, Aghi MK, Vogelbaum MA, Cloughesy TF, Chang SM, Kesari S, Mikkelsen T, Kalkanis SN, Landolfi JC, Elder JB, Chiocca EA, Gruber HE, et al. Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. Journal of Clinical Oncology. 32: 3078-3078. DOI: 10.1200/Jco.2014.32.15_Suppl.3078 |
0.396 |
|
| 2014 |
Lin NU, Gabrail NY, Sarantopoulos J, Schwartzberg LS, Kesari S, Bates SE, Anders CK, Elias AD, Castaigne J, Iordanova V, Lawrence B, Kurzrock R. Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. Journal of Clinical Oncology. 32: 2523-2523. DOI: 10.1200/Jco.2014.32.15_Suppl.2523 |
0.388 |
|
| 2014 |
Pingle SC, Sultana Z, Jiang P, Mukthavaram R, Chao Y, Abbasi T, Kapoor S, Kumar A, Usmani S, Agrawal A, Vali S, Kesari S. Predicting GBM response to targeted therapeutics using simulation with ex vivo validations. Journal of Clinical Oncology. 32: 2041-2041. DOI: 10.1200/Jco.2014.32.15_Suppl.2041 |
0.316 |
|
| 2014 |
Kesari S, Xiu J, Spetzer DB, Ghazalpour A, Gatalica Z, Sanai N. Results of comprehensive molecular profiling of gliomas and the potential therapeutic implications. Journal of Clinical Oncology. 32: 2013-2013. DOI: 10.1200/Jco.2014.32.15_Suppl.2013 |
0.36 |
|
| 2014 |
Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu J, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, ... ... Kesari S, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. Journal of Clinical Oncology. 32: 2005-2005. DOI: 10.1200/Jco.2014.32.15_Suppl.2005 |
0.356 |
|
| 2014 |
Lee EQ, Muzikansky A, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty LM, LaFrankie DC, Pulverenti J, Smith KH, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Journal of Clinical Oncology. 32: 2004-2004. DOI: 10.1200/Jco.2014.32.15_Suppl.2004 |
0.302 |
|
| 2014 |
Pingle SC, Pastorino S, Muktharavam R, Jiang P, Chao Y, Abbasi T, Vali S, Kesari S. Abstract 5339: Deterministic in silico modeling predicts sensitivity of glioblastoma to targeted therapy Cancer Research. 74: 5339-5339. DOI: 10.1158/1538-7445.Am2014-5339 |
0.362 |
|
| 2014 |
Pastorino S, Pingle SC, Langley E, Kim P, Juarez T, Jiang P, Tucker C, Yang T, Saria M, Singh S, Kesari S. Abstract 4652: Cerebrospinal fluid pharmacokinetics and pharmacodynamics following high-dose erlotinib treatment in brain cancer patients Cancer Research. 74: 4652-4652. DOI: 10.1158/1538-7445.Am2014-4652 |
0.363 |
|
| 2014 |
Jiang P, Mukthavavam R, Nomura N, Pingle SC, Kesari S. Abstract 1628: Direct anti-cancer effects of zoledronic acid on human cancer cell Cancer Research. 74: 1628-1628. DOI: 10.1158/1538-7445.Am2014-1628 |
0.329 |
|
| 2014 |
Stupp R, Wong E, Scott C, Taillibert S, Kanner A, Kesari S, Ram Z. NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou265.40 |
0.334 |
|
| 2014 |
Cloughesy TF, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Liau LM, Chen CC, Bloomfield S, Piccioni D, Chiocca EA, Foltz G, Robbins JM, Ostertag D, Jolly DJ, et al. IT-05 * ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION Neuro-Oncology. 16: v110-v111. DOI: 10.1093/Neuonc/Nou258.4 |
0.406 |
|
| 2014 |
Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, ... ... Kesari S, et al. At-60A Randomized Double Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell (Dc) Vaccine Ict-107 Following Standard Treatment In Newly Diagnosed Patients With Gbm Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.59 |
0.324 |
|
| 2014 |
Aghi M, Vogelbaum MA, Kesari S, Chen CC, Liau LM, Piccioni D, Portnow J, Chang S, Robbins JM, Boyce T, Huang TT, Pertschuk D, Ostertag D, Cloughesy TF. AT-02 * INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584) Neuro-Oncology. 16: v8-v8. DOI: 10.1093/Neuonc/Nou237.2 |
0.356 |
|
| 2014 |
Kesari S, Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao Y, Pastorino S, Jiang P, Pingle SC, Wrasidlo W, Makale M. DEVELOPMENT OF NOVEL SMALL MOLECULES THAT TARGET GLIOBLASTOMA STEM CELLS Neuro-Oncology. 16: iii17-iii17. DOI: 10.1093/Neuonc/Nou206.61 |
0.303 |
|
| 2013 |
Hu J, Kesari S. Strategies for overcoming the blood-brain barrier for the treatment of brain metastases. Cns Oncology. 2: 87-98. PMID 25054359 DOI: 10.2217/Cns.12.37 |
0.344 |
|
| 2013 |
Mukthavaram R, Jiang P, Saklecha R, Simberg D, Bharati IS, Nomura N, Chao Y, Pastorino S, Pingle SC, Fogal V, Wrasidlo W, Makale M, Kesari S. High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. International Journal of Nanomedicine. 8: 3991-4006. PMID 24174874 DOI: 10.2147/Ijn.S51949 |
0.347 |
|
| 2013 |
Piccioni DE, Kesari S. Clinical trials of viral therapy for malignant gliomas. Expert Review of Anticancer Therapy. 13: 1297-305. PMID 24138481 DOI: 10.1586/14737140.2013.851160 |
0.329 |
|
| 2013 |
Farid N, Almeida-Freitas DB, White NS, McDonald CR, Muller KA, Vandenberg SR, Kesari S, Dale AM. Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. Frontiers in Oncology. 3: 258. PMID 24137566 DOI: 10.3389/Fonc.2013.00258 |
0.341 |
|
| 2013 |
Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. Journal of Neuro-Oncology. 115: 71-7. PMID 23828279 DOI: 10.1007/S11060-013-1196-1 |
0.358 |
|
| 2013 |
Davis DL, Kesari S, Soskolne CL, Miller AB, Stein Y. Swedish review strengthens grounds for concluding that radiation from cellular and cordless phones is a probable human carcinogen. Pathophysiology : the Official Journal of the International Society For Pathophysiology / Isp. 20: 123-9. PMID 23664410 DOI: 10.1016/J.Pathophys.2013.03.001 |
0.308 |
|
| 2013 |
Shi G, Cui W, Benchimol M, Liu YT, Mattrey RF, Mukthavaram R, Kesari S, Esener SC, Simberg D. Isolation of rare tumor cells from blood cells with buoyant immuno-microbubbles. Plos One. 8: e58017. PMID 23516425 DOI: 10.1371/Journal.Pone.0058017 |
0.346 |
|
| 2013 |
Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, ... ... Kesari S, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. Journal of Neurosurgery. 118: 1183-7. PMID 23451905 DOI: 10.3171/2013.1.Jns12397 |
0.376 |
|
| 2013 |
Yost SE, Pastorino S, Rozenzhak S, Smith EN, Chao YS, Jiang P, Kesari S, Frazer KA, Harismendy O. High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. Plos One. 8: e56185. PMID 23441165 DOI: 10.1371/Journal.Pone.0056185 |
0.381 |
|
| 2013 |
McDonald CR, White NS, Farid N, Lai G, Kuperman JM, Bartsch H, Hagler DJ, Kesari S, Carter BS, Chen CC, Dale AM. Recovery of white matter tracts in regions of peritumoral FLAIR hyperintensity with use of restriction spectrum imaging. Ajnr. American Journal of Neuroradiology. 34: 1157-63. PMID 23275591 DOI: 10.3174/Ajnr.A3372 |
0.304 |
|
| 2013 |
White NS, McDonald CR, Farid N, Kuperman JM, Kesari S, Dale AM. Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using "restriction spectrum imaging": quantitative comparison with high B-value DWI and ADC. Ajnr. American Journal of Neuroradiology. 34: 958-64, S1. PMID 23139079 DOI: 10.3174/Ajnr.A3327 |
0.35 |
|
| 2013 |
Saria MG, Corle C, Rush T, Kesari S. Improved survival of patients with glioblastoma at NCI-designated clinical cancer centers. Journal of Clinical Oncology. 31: 122-122. DOI: 10.1200/Jco.2013.31.31_Suppl.122 |
0.36 |
|
| 2013 |
Carpentier AF, Brandes AA, Kesari S, Sepúlveda JM, Wheeler H, Chinot OL, Cher L, Steinbach JP, Specenier PM, Cleverly A, Tomlin I, Desaiah D, Lahn MMF, Wick W. Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression. Journal of Clinical Oncology. 31: 2061-2061. DOI: 10.1200/Jco.2013.31.15_Suppl.2061 |
0.316 |
|
| 2013 |
Jiang P, Mukthavavam R, Chao Y, Nomura N, Fogal V, Pastorino S, Summit I, Kesari S. Abstract 1856: Preclinical study for statins as anticancer drug. Cancer Research. 73: 1856-1856. DOI: 10.1158/1538-7445.Am2013-1856 |
0.342 |
|
| 2013 |
Lin NU, Schwartzberg L, Kesari S, Elias A, Anders C, Raizer J, Kozloff M, Amiri-Kordestani L. Abstract B76: A phase II study of ANG1005, a novel, brain-penetrant taxane derivative, in breast cancer patients with brain metastases. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B76 |
0.356 |
|
| 2012 |
Elbabaa SK, Gokden M, Crawford JR, Kesari S, Saad AG. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature. Journal of Neurosurgery. Pediatrics. 10: 281-90. PMID 22900483 DOI: 10.3171/2012.7.Peds1251 |
0.314 |
|
| 2012 |
Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2307-13. PMID 22547604 DOI: 10.1200/Jco.2011.39.1540 |
0.328 |
|
| 2012 |
Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S, Krichevsky AM. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology. 14: 689-700. PMID 22492962 DOI: 10.1093/Neuonc/Nos074 |
0.354 |
|
| 2012 |
Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, Kesari S, Dörner L. Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. Neuro-Oncology. 14: 482-90. PMID 22319220 DOI: 10.1093/Neuonc/Nos003 |
0.31 |
|
| 2012 |
Cai P, Mahta A, Kim RY, Kesari S. Paraganglioma with intracranial metastasis: a case report and review of the literature. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 33: 1183-4. PMID 22187335 DOI: 10.1007/S10072-011-0879-7 |
0.316 |
|
| 2012 |
Pan H, Alksne J, Mundt AJ, Murphy KT, Cornell M, Kesari S, Lawson JD. Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study. Medical Oncology (Northwood, London, England). 29: 2040-5. PMID 22108847 DOI: 10.1007/S12032-011-0116-5 |
0.354 |
|
| 2012 |
Grewal J, Saria MG, Kesari S. Novel approaches to treating leptomeningeal metastases. Journal of Neuro-Oncology. 106: 225-34. PMID 21874597 DOI: 10.1007/S11060-011-0686-2 |
0.346 |
|
| 2012 |
Corle C, Makale M, Kesari S. Cell phones and glioma risk: a review of the evidence. Journal of Neuro-Oncology. 106: 1-13. PMID 21853424 DOI: 10.1007/S11060-011-0663-9 |
0.392 |
|
| 2012 |
Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S. Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. Journal of Neuro-Oncology. 106: 427-9. PMID 21833801 DOI: 10.1007/S11060-011-0675-5 |
0.342 |
|
| 2012 |
Mahta A, Kim RY, Kesari S. Fourth ventricular choroid plexus papilloma. Medical Oncology (Northwood, London, England). 29: 1285-6. PMID 21630054 DOI: 10.1007/S12032-011-9994-9 |
0.352 |
|
| 2012 |
Hu XQ, Imitola J, Kim RY, Mahta A, Kesari S. Brain metastasis from ovarian cancer: case report and review of the literature. Medical Oncology (Northwood, London, England). 29: 1250-2. PMID 21380785 DOI: 10.1007/S12032-011-9876-1 |
0.314 |
|
| 2012 |
Hammond S, Drappatz J, Lee E, Muzikansky A, Weiss S, Kesari S, Wong E, Fadul C, Norden A, Beroukhim R, Alexander B, Ruland S, Ciampa A, Lafrankie D, Doherty L, et al. Interim Analysis of a Randomized Placebo-Controlled Pilot Trial of Armodafinil for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or without Standard Chemotherapy Treatment (P07.104) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.104 |
0.319 |
|
| 2012 |
Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, et al. A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2107 |
0.387 |
|
| 2012 |
Kesari S, Taillibert S, Kanner A, Weinberg U. Phase III trial of tumor-treating fields (TTFields) together with temozolomide compared with temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma multiforme (NCT00916409). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2106 |
0.385 |
|
| 2012 |
Pertschuk D, Cloughesy TF, Chang SM, Aghi MK, Vogelbaum MA, Liau LM, Shafa BB, Yong WH, Chen C, Kesari S, Ibanez CE, Perez OD, Robbins JM, Jolly DJ, Gruber HE. Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma. Journal of Clinical Oncology. 30: 2101-2101. DOI: 10.1200/Jco.2012.30.15_Suppl.2101 |
0.383 |
|
| 2012 |
Scott BJ, Feely H, Brown T, Vugt VV, Kim R, Fanta PT, Bazhenova L, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for the treatment of leptomeningeal metastasis from solid tumors. Journal of Clinical Oncology. 30: 2052-2052. DOI: 10.1200/Jco.2012.30.15_Suppl.2052 |
0.399 |
|
| 2012 |
Verma IM, Soda Y, Friedmann-Morvinski D, Pastorino S, Kesari S. Abstract SY41-01: Tumor-endothelial transdifferentiation Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy41-01 |
0.374 |
|
| 2012 |
Pastorino S, Chao Y, Gallagher M, Mukthavaram R, Fogal V, Bharati I, Makale M, Jiang P, Kesari S. Abstract 5203: Lineage-specific mechanisms regulating PDGFRα oncogenic activity in glioblastoma Cancer Research. 72: 5203-5203. DOI: 10.1158/1538-7445.Am2012-5203 |
0.416 |
|
| 2012 |
Jiang P, Mukthavaram R, Summitt I, Chao Y, Gallagher M, Kim R, Pastorino S, Kesari S. Abstract 3680: Drug screening for glioblastoma patients Cancer Research. 72: 3680-3680. DOI: 10.1158/1538-7445.Am2012-3680 |
0.321 |
|
| 2012 |
Fogal V, Chao YS, Pastorino S, Wang L, Jian P, Mukthavaram R, Gallagher M, Summitt IB, Kesari S. Abstract 1115: p32 is a downstream effector of c-Myc induced glutamine addiction Cancer Research. 72: 1115-1115. DOI: 10.1158/1538-7445.Am2012-1115 |
0.326 |
|
| 2012 |
Lin N, Schwartzberg L, Kesari S, Yardley D, Verma S, Anders C, Shih T, Shen Y, Miller K. Abstract P3-12-04: A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-12-04 |
0.354 |
|
| 2011 |
Grewal J, Saria M, Grewal HK, Kesari S. Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome. Clinical Investigation. 1: 1391-1402. PMID 22396850 DOI: 10.4155/Cli.11.115 |
0.326 |
|
| 2011 |
Kesari S, Advani SJ, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC. DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. Future Oncology (London, England). 7: 1335-46. PMID 22044206 DOI: 10.2217/Fon.11.111 |
0.319 |
|
| 2011 |
Ziegler DS, Keating J, Kesari S, Fast EM, Zawel L, Ramakrishna N, Barnes J, Kieran MW, Veldhuijzen van Zanten SE, Kung AL. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro-Oncology. 13: 820-9. PMID 21724651 DOI: 10.1093/Neuonc/Nor066 |
0.393 |
|
| 2011 |
Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. Journal of Neurosurgery. 115: 730-6. PMID 21721878 DOI: 10.3171/2011.5.Jns101768 |
0.368 |
|
| 2011 |
Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Review of Clinical Pharmacology. 4: 233-42. PMID 21666852 DOI: 10.1586/Ecp.11.1 |
0.421 |
|
| 2011 |
Hu A, Xu Z, Kim RY, Nguyen A, Lee JW, Kesari S. Seizure control: A secondary benefit of chemotherapeutic temozolomide in brain cancer patients Epilepsy Research. 95: 270-272. PMID 21549564 DOI: 10.1016/J.Eplepsyres.2011.03.018 |
0.349 |
|
| 2011 |
Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel PS, Hawkins C, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. The Journal of Experimental Medicine. 208: 689-702. PMID 21464220 DOI: 10.1084/Jem.20102099 |
0.36 |
|
| 2011 |
Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 4274-80. PMID 21262804 DOI: 10.1073/Pnas.1016030108 |
0.359 |
|
| 2011 |
Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas Journal of Neuro-Oncology. 104: 179-189. PMID 21246394 DOI: 10.1007/S11060-010-0502-4 |
0.372 |
|
| 2011 |
Wong K, Young GS, Makale M, Hu X, Yildirim N, Cui K, Wong ST, Kesari S. Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imaging. Journal of Neuro-Oncology. 104: 473-81. PMID 21240539 DOI: 10.1007/S11060-010-0517-X |
0.332 |
|
| 2011 |
Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, ... Kesari S, et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 81: 1422-7. PMID 20934264 DOI: 10.1016/J.Ijrobp.2010.07.1997 |
0.324 |
|
| 2010 |
Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, Wu L, Griffin JD. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes & Cancer. 1: 822-35. PMID 21127729 DOI: 10.1177/1947601910383564 |
0.315 |
|
| 2010 |
Dietrich J, Diamond EL, Kesari S. Glioma stem cell signaling: Therapeutic opportunities and challenges Expert Review of Anticancer Therapy. 10: 709-722. PMID 20470003 DOI: 10.1586/Era.09.190 |
0.36 |
|
| 2010 |
Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM, Warfield SK, Kikinis R, Bromfield EB. Morphological characteristics of brain tumors causing seizures. Archives of Neurology. 67: 336-42. PMID 20212231 DOI: 10.1001/Archneurol.2010.2 |
0.332 |
|
| 2010 |
Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, Shi Y, Wang H, Huang X, Wong ST, Wang Y, Kesari S, Ji RR, Xu X. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. European Journal of Cancer (Oxford, England : 1990). 46: 1132-43. PMID 20156674 DOI: 10.1016/J.Ejca.2010.01.014 |
0.334 |
|
| 2010 |
Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 78: 85-90. PMID 20137866 DOI: 10.1016/J.Ijrobp.2009.07.1741 |
0.326 |
|
| 2009 |
Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 73: 1551-8. PMID 19901246 DOI: 10.1212/Wnl.0B013E3181C0D4A1 |
0.302 |
|
| 2009 |
Glantz M, Kesari S, Recht L, Fleischhack G, Van Horn A. Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay. Seminars in Oncology. 36: S17-24. PMID 19660679 DOI: 10.1053/J.Seminoncol.2009.05.003 |
0.412 |
|
| 2009 |
Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3518-25. PMID 19528374 DOI: 10.1200/Jco.2008.18.3087 |
0.343 |
|
| 2009 |
Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research. 69: 3472-81. PMID 19351838 DOI: 10.1158/0008-5472.Can-08-3886 |
0.384 |
|
| 2009 |
Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, LaFrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-Oncology. 11: 550-555. PMID 19332770 DOI: 10.1215/15228517-2009-006 |
0.384 |
|
| 2009 |
Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010 |
0.386 |
|
| 2009 |
Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 330-7. PMID 19118062 DOI: 10.1158/1078-0432.Ccr-08-0888 |
0.367 |
|
| 2009 |
Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma Journal of Neuro-Oncology. 92: 149-155. PMID 19043778 DOI: 10.1007/S11060-008-9745-8 |
0.355 |
|
| 2009 |
Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O. Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. Journal of Neuro-Oncology. 91: 213-20. PMID 18807224 DOI: 10.1007/S11060-008-9701-7 |
0.341 |
|
| 2009 |
Norden AD, Drappatz J, Ciampa AS, Doherty L, Lafrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma Neuro-Oncology. 11: 92-95. PMID 18757774 DOI: 10.1215/15228517-2008-071 |
0.334 |
|
| 2009 |
Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro-Oncology. 11: 109-21. PMID 18682579 DOI: 10.1215/15228517-2008-060 |
0.359 |
|
| 2009 |
Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 73: 222-7. PMID 18513880 DOI: 10.1016/J.Ijrobp.2008.03.046 |
0.354 |
|
| 2009 |
Zhao H, Zhu J, Cui K, Xu X, O'Brien M, Wong KK, Kesari S, Xia W, Wong STC. Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid β protein Cancer Cell International. 9. DOI: 10.1186/1475-2867-9-15 |
0.324 |
|
| 2009 |
Dietrich J, Kesari S. Effect of cancer treatment on neural stem and progenitor cells Cancer Treatment and Research. 150: 81-95. DOI: 10.1007/B109924_6 |
0.338 |
|
| 2008 |
Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4843-4. PMID 18779600 DOI: 10.1200/Jco.2008.18.1776 |
0.32 |
|
| 2008 |
Wen PY, Kesari S. Malignant Gliomas in Adults The New England Journal of Medicine. 359: 492-507. PMID 18669428 DOI: 10.1056/Nejmra0708126 |
0.3 |
|
| 2008 |
Dietrich J, Imitola J, Kesari S. Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. Nature Clinical Practice. Oncology. 5: 393-404. PMID 18521117 DOI: 10.1038/Ncponc1132 |
0.339 |
|
| 2008 |
Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology. 10: 300-8. PMID 18403492 DOI: 10.1215/15228517-2008-005 |
0.346 |
|
| 2008 |
Grewal J, Kesari S. Breast cancer surface receptors predict risk for developing brain metastasis and subsequent prognosis Breast Cancer Research. 10: 104-104. PMID 18373884 DOI: 10.1186/Bcr1868 |
0.308 |
|
| 2008 |
Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. Journal of Neuro-Oncology. 88: 175-83. PMID 18365144 DOI: 10.1007/S11060-008-9545-1 |
0.36 |
|
| 2008 |
Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 70: 779-87. PMID 18316689 DOI: 10.1212/01.Wnl.0000304121.57857.38 |
0.41 |
|
| 2008 |
Akar S, Drappatz J, Hsu L, Blinder RA, Black PM, Kesari S. Hypertrophic olivary degeneration after resection of a cerebellar tumor Journal of Neuro-Oncology. 87: 341-345. PMID 18217209 DOI: 10.1007/S11060-008-9523-7 |
0.338 |
|
| 2007 |
Evans CL, Xu X, Kesari S, Xie XS, Wong ST, Young GS. Chemically-selective imaging of brain structures with CARS microscopy. Optics Express. 15: 12076-87. PMID 19547572 DOI: 10.1364/Oe.15.012076 |
0.311 |
|
| 2007 |
Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical Management of Brain Tumor Patients Neurologic Clinics. 25: 1035-1071. PMID 17964025 DOI: 10.1016/J.Ncl.2007.07.015 |
0.339 |
|
| 2007 |
Sauvageot CM, Kesari S, Stiles CD. Molecular pathogenesis of adult brain tumors and the role of stem cells. Neurologic Clinics. 25: 891-924, vii. PMID 17964020 DOI: 10.1016/J.Ncl.2007.07.014 |
0.382 |
|
| 2007 |
Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncology. 9: 354-63. PMID 17452651 DOI: 10.1215/15228517-2007-006 |
0.376 |
|
| 2007 |
Kesari S, Jackson-Grusby L, Stiles CD. "Smad"eningly erratic: target gene methylation determines whether TGFbeta promotes or suppresses malignant glioma. Developmental Cell. 12: 324-5. PMID 17336898 DOI: 10.1016/J.Devcel.2007.02.008 |
0.34 |
|
| 2007 |
Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, Kesari S. Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. Journal of Neuro-Oncology. 84: 179-83. PMID 17332945 DOI: 10.1007/S11060-007-9354-Y |
0.344 |
|
| 2007 |
Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 53: 503-17. PMID 17296553 DOI: 10.1016/J.Neuron.2007.01.009 |
0.31 |
|
| 2007 |
Narin O, Drappatz J, Doherty LM, Wen PY, Kesari S. Cerebrospinal fluid spread of anaplastic glioma. Journal of Clinical Oncology. 25: 596-597. PMID 17290068 DOI: 10.1200/Jco.2006.09.3096 |
0.389 |
|
| 2007 |
Gerin F, Baloglu O, Morgan JA, Kesari S. Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor. Journal of Neuro-Oncology. 82: 227-228. PMID 17106648 DOI: 10.1007/S11060-006-9277-Z |
0.326 |
|
| 2006 |
Doherty L, Gigas DC, Kesari S, Drappatz J, Kim RS, Zimmerman J, Ostrowsky L, Wen PY. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 67: 156-158. PMID 16832099 DOI: 10.1212/01.Wnl.0000223844.77636.29 |
0.37 |
|
| 2006 |
Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors Journal of Neuro-Oncology. 80: 313-332. PMID 16807780 DOI: 10.1007/S11060-006-9193-2 |
0.346 |
|
| 2006 |
Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Current Oncology Reports. 8: 58-70. PMID 16464405 DOI: 10.1007/S11912-006-0011-Y |
0.346 |
|
| 2006 |
Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-Oncology. 8: 38-46. PMID 16443946 DOI: 10.1215/S1522851705000529 |
0.366 |
|
| 2006 |
Rosovsky RP, Wen P, Kesari S, Cott EMV, Kuter DJ. The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism. Blood. 108: 4097-4097. DOI: 10.1182/Blood.V108.11.4097.4097 |
0.378 |
|
| 2005 |
Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Current Neurology and Neuroscience Reports. 5: 186-97. PMID 15865884 DOI: 10.1007/S11910-005-0046-8 |
0.346 |
|
| 2004 |
Mrugala MM, Kesari S, Ramakrishna N, Wen PY. Therapy for recurrent malignant glioma in adults. Expert Review of Anticancer Therapy. 4: 759-782. PMID 15485312 DOI: 10.1586/14737140.4.5.759 |
0.385 |
|
| Show low-probability matches. |